Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
Company receives Complete Response Letter from FDA for Deramiocel BLA Conference call and webcast Monday, November 23, at 8:30 a.m. ET SAN DIEGO, Nov.
Tagged nasdaq caprClear
Company receives Complete Response Letter from FDA for Deramiocel BLA Conference call and webcast Monday, November 23, at 8:30 a.m. ET SAN DIEGO, Nov.